Denver, Colorado – Advances in HIV treatment are offering hope for a future with significantly reduced dosing schedules. Recent findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) suggest that three experimental injectable antiretrovirals could potentially allow individuals living with HIV to receive treatment just twice a year. This represents a substantial shift from current regimens, which often require daily pills or monthly injections.
The research focuses on a novel capsid inhibitor, VH-499, developed by ViiV Healthcare, alongside two next-generation integrase inhibitors: VH-184, also from ViiV Healthcare, and GS-3242, from Gilead Sciences. Pharmacokinetic data indicates these drugs could maintain therapeutic levels in the body with injections administered only every six months, dramatically simplifying treatment and potentially improving adherence.
Currently, the longest-acting HIV treatment available involves injections of cabotegravir and rilpivirine, administered either monthly or every other month. Gilead Sciences’ lenacapavir offers a twice-yearly injection option, but currently lacks a complementary long-acting partner drug for a complete regimen. These latest investigational drugs aim to fill that gap, offering the possibility of a fully long-acting, twice-yearly treatment course.
VH-499, the investigational capsid inhibitor, is particularly noteworthy as it doesn’t interfere with or induce CYP3A4, an enzyme responsible for metabolizing many medications. This characteristic suggests a lower risk of drug-drug interactions, a crucial consideration for individuals managing HIV alongside other health conditions and medications.
Promising Early Results and Next Steps
According to study results presented at CROI 2026, all three drugs – VH-499, VH-184, and GS-3242 – demonstrated a favorable safety profile and were generally well-tolerated by participants. Phase II clinical trials are anticipated to begin this year, which will further evaluate the efficacy and safety of these compounds in larger populations. These trials are critical to confirming the initial pharmacokinetic data and assessing long-term outcomes.
ViiV Healthcare’s VH184 is a third-generation integrase strand transfer inhibitor (INSTI) and has shown potential for up to six-month dosing intervals in early studies. In-vitro data also suggest improved potency and a better resistance profile compared to bictegravir, a commonly used integrase inhibitor. ViiV Healthcare announced these findings in late February 2026.
The Potential Impact of Ultra-Long-Acting Therapies
The development of ultra-long-acting (ULA) antiretroviral therapies represents a significant step forward in HIV treatment. Reducing the frequency of medication administration can address challenges related to adherence, a major factor influencing treatment success. More convenient regimens may also improve the quality of life for individuals living with HIV, reducing the daily burden of managing their condition. aidsmap.com highlights the potential for these new therapies to become components of future long-acting HIV treatment regimens.
Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, emphasized the company’s commitment to advancing innovative long-acting HIV therapies, stating that their research and development efforts are focused on making HIV treatment a smaller, less frequent part of people’s lives. BioSpace reported on this statement.
While these findings are promising, it’s important to remember that these drugs are still in the early stages of development. The success of Phase II trials will be crucial in determining their ultimate role in HIV treatment. Further research will also be needed to understand the long-term effects and potential challenges associated with these new regimens.
The ongoing research into VH-499, VH-184, and GS-3242 underscores the continued innovation in the field of HIV treatment. As these investigational drugs progress through clinical trials, they offer a glimpse into a future where managing HIV may become significantly easier and more convenient for those living with the virus.
Disclaimer: This article provides informational content about medical research and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions you may have regarding a medical condition.
What are your thoughts on the potential of twice-yearly HIV treatment? Share your comments below, and please share this article with your network.
